Evidence of traditionality of Brazilian medicinal plants: The case studies of Stryphnodendron adstringens (Mart.) Coville (barbatimão) barks and Copaifera spp. (copaíba) oleoresin in wound healing.

ETHNOPHARMACOLOGICAL RELEVANCE: The World Health Organization (WHO) recognizes the potential of plants used in secular traditional medicine and considers this an important source of evidence to assess their effectiveness and safety. Brazil is rich in biodiversity and traditional uses based on the Amerindian culture. However, many processes started with the arrival of the Portuguese in the year 1500. The successive economic cycles, for example, led to destruction of native vegetation and an intense cultural erosion. As a consequence, the information about the use of plants in the past centuries are dispersed and without interpretation. In this study a methodology to evidence the traditionality of Brazilian plants was demonstrated using data about barbatimão barks (Stryphnodendron adstringens (Mart.) Coville - Fabaceae) and Copaiba oleoresin (Copaifera spp. - Fabaceae) in wound healing, was established. MATERIAL AND METHODS: Data about use of the plants were recovered from bibliography published between 1576 and 2011. The books (101) were classified using weights, considering the date of publication and the source of Information. Older books that describe primary information received weight 10, while books written more recently and with secondary information received weight 0.4. A score for each category of medicinal use was calculated based on the books weights and the frequency of citation. A review about the current use of both plants was also performed from ethnobotanical studies published in journals. RESULTS AND DISCUSSION: The traditional secular use of barks of barbatimão and oleoresin of copaiba to treat wounds was confirmed based on the historic bibliographic research. The most frequent use of barbatimão in a timeline of 500 years of Brazil's history, was as astringent, whereas for copaíba was as healing of skin and mucosal lesions. The continuous and current use of these plants to treat wounds, confirmed by recent ethnobotanical studies, is an indicative of the resilience of these remedies and their effectiveness. CONCLUSION: The use of preparations containing barbatimão barks and copaiba oleoresin can be considered effective in the treatment of wounds. Nonetheless, it is necessary to improve the quality of the formulas as established by WHO.

Plants from the Brazilian Traditional Medicine: species from the books of the Polish physician Piotr Czerniewicz (Pedro Luiz Napoleão Chernoviz, 1812-1881)

Abstract The Brazilian flora is very rich in medicinal plants, and much information about the traditional use of the Brazilian plants is only available from early literature and we are facing a rapid process of loss of biodiversity. To retrieve data about useful plants registered in the books of the Polish physicist P.L.N. Chernoviz, who lived in Brazil for 15 years in the 19th century. The aim is to improve our knowledge about Brazilian plants, and to ensure the benefits of sharing it with potential users. Data about Brazilian plants were obtained from six editions of the book Formulary and Medical Guide (Formulário e Guia Médico), published in 1864, 1874, 1888, 1892, 1897 and 1920. All this information was then organized in boxes, and correlated with pharmacological studies from PubMed and Lilacs. A total of 238 species were recorded and 117 different traditional uses were registered for the plants. The most common uses were to treat general skin diseases and intermittent fevers, as purgative, diuretics and andidiarrheal. From the total, only 61 species (25.6%) have been to date subject to pharmacological studies and had their activities confirmed. Chernoviz books represent an important source of data about plants used in traditional medicine of Brazil. Their records were collected at a time when Brazil's native vegetation was still largely intact, and traditional medicine was practiced based on native plants. We argue that these plants must be prioritized in development of medicines, submitting them to clinical studies or by considering their traditionality, as established by WHO. Strategies for the protection of the traditional knowledge are also necessary.